Ben Tre Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Ben Tre Pharmaceutical's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 13.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2020 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Ben Tre Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 20 | 828,640 | 16,892 | 170,173 | 0 |
| 31 Mar 20 | 825,161 | 20,644 | 166,638 | 0 |
| 31 Dec 19 | 800,500 | 21,396 | 155,629 | 0 |
| 30 Sep 19 | 786,073 | 22,218 | 158,238 | 0 |
| 30 Jun 19 | 813,116 | 21,993 | 155,983 | 0 |
| 31 Mar 19 | 806,118 | 21,904 | 150,843 | 0 |
| 31 Dec 18 | 809,914 | 20,193 | 153,771 | 0 |
| 30 Sep 18 | 789,993 | 25,707 | 148,360 | 0 |
| 30 Jun 18 | 759,046 | 28,075 | 154,274 | 0 |
| 31 Mar 18 | 795,642 | 27,416 | 157,866 | 0 |
| 31 Dec 17 | 800,114 | 28,737 | 154,783 | 0 |
| 30 Sep 17 | 752,713 | 20,745 | 141,773 | 0 |
| 30 Jun 17 | 715,361 | 19,438 | 123,043 | 0 |
| 31 Mar 17 | 638,424 | 22,475 | 114,799 | 0 |
| 31 Dec 16 | 580,517 | 23,662 | 107,815 | 0 |
| 30 Sep 16 | 567,723 | 28,232 | 125,451 | 0 |
| 30 Jun 16 | 558,420 | 25,129 | 128,007 | 0 |
| 31 Mar 16 | 555,706 | 25,195 | 122,479 | 0 |
| 31 Dec 15 | 552,116 | 22,203 | 122,730 | 0 |
| 30 Sep 15 | 536,757 | 13,497 | 120,718 | 0 |
| 30 Jun 15 | 529,245 | 15,075 | 117,224 | 0 |
| 31 Mar 15 | 524,663 | 12,236 | 113,915 | 0 |
| 31 Dec 14 | 523,255 | 11,368 | 107,429 | 0 |
| 30 Sep 14 | 474,235 | 11,191 | 92,878 | 0 |
| 30 Jun 14 | 485,215 | 10,746 | 94,244 | 0 |
| 31 Mar 14 | 512,791 | 11,223 | 99,448 | 0 |
| 31 Dec 13 | 530,370 | 11,033 | 104,252 | 0 |
| 30 Sep 13 | 599,013 | 12,396 | 103,177 | 0 |
| 30 Jun 13 | 609,042 | 12,658 | 103,270 | 0 |
Quality Earnings: DBT has a high level of non-cash earnings.
Growing Profit Margin: Insufficient data to determine if DBT's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if DBT's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare DBT's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if DBT's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: DBT has a negative Return on Equity (0%), as it is currently unprofitable.